Related references
Note: Only part of the references are listed.Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients
Armin Sebastian Guntner et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries
Lindsey M. Hoffman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma
Rikke D. Rasmussen et al.
MOLECULAR ONCOLOGY (2016)
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes
David Castel et al.
ACTA NEUROPATHOLOGICA (2015)
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
Catherine S. Grasso et al.
NATURE MEDICINE (2015)
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
Pawel Buczkowicz et al.
NATURE GENETICS (2014)
SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition
Jesse E. Hanson et al.
PLOS ONE (2013)
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
Gang Wu et al.
NATURE GENETICS (2012)
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas
Daphne A. Haas-Kogan et al.
NEURO-ONCOLOGY (2011)
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium
Ian F. Pollack et al.
NEURO-ONCOLOGY (2011)
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group
Kenneth J. Cohen et al.
NEURO-ONCOLOGY (2011)
SAHA Decreases HDAC 2 and 4 Levels In Vivo and Improves Molecular Phenotypes in the R6/2 Mouse Model of Huntington's Disease
Michal Mielcarek et al.
PLOS ONE (2011)
Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Shortening the timeline of pediatric phase I trials: The rolling six design
Jeffrey M. Skolnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: A children's oncology group phase II study
David N. Korones et al.
PEDIATRIC BLOOD & CANCER (2008)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model
Hasan C. Ugur et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Discovery and development of SAHA as an anticancer agent
P. A. Marks
ONCOGENE (2007)
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor:: Effects on gene expression and growth of glioma cells in vitro and in vivo
Dong Yin et al.
CLINICAL CANCER RESEARCH (2007)
Diffuse and focal brain stem tumors in childhood: prognostic factors and surgical outcome
A. Sandri et al.
CHILDS NERVOUS SYSTEM (2006)
Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma
Susan E. Spiller et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Diffuse brainstem glioma in children: critical review of clinical trials
D Hargrove et al.
LANCET ONCOLOGY (2006)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas - Results of a French Society of Paediatric Oncology Phase II study
V Bernier-Chastagner et al.
CANCER (2005)
A phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas
RJ Packer et al.
CANCER (2005)
Etoposide, vincristine, and cyclosporin a with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: A pediatric oncology group Phase I study
ML Greenberg et al.
PEDIATRIC BLOOD & CANCER (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo
IY Eyüpoglu et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Modulation of radiation response by histone deacetylase inhibition
P Chinnaiyan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children - Results of a multiinstitutional study (SJHG-98)
A Broniscer et al.
CANCER (2005)
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease
E Hockly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Treatment of paediatric pontine glioma with oral trophosphamide and etoposide
JEA Wolff et al.
BRITISH JOURNAL OF CANCER (2002)
Preradiation chemotherapy in primary high-risk brainstem tumors: Phase II study CCG-9941 of the children's cancer group
MT Jennings et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Societe Francaise d'Oncologie Pediatrique
F Doz et al.
EUROPEAN JOURNAL OF CANCER (2002)
Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas:: Results of a Brazilian cooperative study
A Broniscer et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
